SpringWorks Therapeutics Cash on Hand 2019-2022 | SWTX

SpringWorks Therapeutics cash on hand from 2019 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
SpringWorks Therapeutics Annual Cash on Hand
(Millions of US $)
2021 $374
2020 $508
2019 $328
2018 $46
SpringWorks Therapeutics Quarterly Cash on Hand
(Millions of US $)
2022-03-31 $348
2021-12-31 $374
2021-09-30 $428
2021-06-30 $463
2021-03-31 $477
2020-12-31 $508
2020-09-30 $277
2020-06-30 $291
2020-03-31 $311
2019-12-31 $328
2019-09-30 $344
2019-06-30
2019-03-31
2018-12-31
2018-09-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.907B $0.035B
SpringWorks Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing life-changing medicines for patients with severe rare diseases and cancer. The company's product pipeline consists of Nirogacestat and Mirdametinib which are in clinical stage. SpringWorks Therapeutics Inc. is based in Stamford, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00